Screener
TG Therapeutics TGTX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Other income | (5,132) | (2,793) | (7,519) | (6,396) |
| Total other expense | 11,440 | 3,923 | 25,872 | 7,077 |
| Net income before taxes | $10,234 | $30,920 | $30,597 | $36,388 |
| Income tax expense | (2,453) | (2,733) | (3,039) | (3,141) |
| Net income | $7,781 | $28,187 | $27,558 | $33,247 |
| Net income per common share: | ||||
| Basic | $0.05 | $0.19 | $0.19 | $0.23 |
| Diluted | $0.05 | $0.17 | $0.17 | $0.20 |
Document
FAQ
- What is TG Therapeutics's income tax?
- TG Therapeutics (TGTX) reported income tax of $2.45M in Q2 2026.
- How has TG Therapeutics's income tax changed year-over-year?
- TG Therapeutics's income tax decreased by 10.2% year-over-year, from $2.73M to $2.45M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about TG Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude